JASMINE MCENTYRE: Open Payments
NPI 1871145912 · LEXINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$608 in 27 payments from 12 companies in 2025. Trend: 2023 $185 · 2024 $323 · 2025 $608
Food & beverage: $608
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $145 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Novo Nordisk Inc | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $55 |
| PFIZER INC. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Merck Sharp & Dohme LLC | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: Auvelity, VRAYLAR, REXULTI, Kerendia, QULIPTA, Wegovy, Ozempic, PREVNAR 20.
Industry payments across NC — which companies pay providers there.
